Diligence memo · auto-generated · as of July 2, 2026
Phylos Bioscience, Inc.
Phylos Bioscience, Inc. has raised $24M over 10 rounds; too few niche peers to rank its valuation yet.
Businessfiled
Phylos Bioscience, Inc. operates in Biotech, based in PORTLAND.
Sub-sector tags: biotech.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Phylos Bioscience, Inc. has raised $24M in disclosed capital across 10 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $25M on 2020-07-01.
Most recent recorded round closed around 2025-12-09.
Valuation (modeled)modeled
Provath models Phylos Bioscience, Inc. at approximately $2.2M (range $1.2M–$3.0M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Too few comparable companies in this niche to rank the valuation fairly yet.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 7 mo ago; this sector typically re-raises about every 11 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 3.1× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 92% of Biotech peers (233 compared).
Modeled value ranks above 71% of those peers.
Closest niche peers: Octave Bioscience Inc, Goodwin Biotechnology, Inc, Cyrus Biotechnology, Inc..
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.